单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
TIL（肿瘤浸润淋巴细胞）过继细胞治疗可在转移性黑色素瘤中诱导持久缓解，然而在体外扩增过程中及回输后，调控肿瘤反应性T细胞命运的克隆和转录动态仍知之甚少。
98.5分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
癌症疫苗：进展、障碍与未来方向
英文原题：Cancer vaccines: advances, hurdles, and future directions.
研究概要
治疗性癌症疫苗利用适应性免疫系统，通过靶向肿瘤特异性抗原来根除恶性肿瘤。
中文摘要
治疗性癌症疫苗利用适应性免疫系统，通过靶向肿瘤特异性抗原清除恶性肿瘤。本综述梳理了癌症疫苗平台的演变——从共享肿瘤相关抗原（TAA）和树突状细胞（DC）疫苗到下一代新抗原-信使核糖核酸（mRNA）疫苗——重点介绍了疫苗递送、抗原发现、计算预测和转化疗效方面的进展。我们探讨了前沿临床数据，包括长寿命T细胞记忆以及在多种癌症类型中的有前景的结果，涵盖胰腺导管腺癌（PDAC）、黑色素瘤、头颈部癌、肾细胞癌（RCC）等。我们讨论了关键挑战，包括肿瘤异质性、生产可扩展性、生物标志物开发和监管框架，并提出一个整合转化生态系统以加速个性化癌症疫苗的采用。
展开英文摘要原文
Therapeutic cancer vaccines harness the adaptive immune system to eradicate malignancies by targeting tumor-specific antigens. This review charts the evolution of cancer vaccine platforms-from shared tumor-associated antigens (TAAs) and dendritic cell (DC) vaccines to next-generation neoantigen-messenger ribonucleic acid (mRNA) vaccines-highlighting advances in vaccine delivery, antigen discovery, computational prediction, and translational efficacy. We explore cutting-edge clinical data, including long-lived T-cell memory and promising outcomes in various cancer types, including pancreatic ductal adenocarcinoma (PDAC), melanoma, head and neck cancers, renal cell carcinoma (RCC), and others. We address critical challenges, including tumor heterogeneity, manufacturing scalability, biomarker development, and regulatory frameworks, and propose an integrated translational ecosystem to accelerate the adoption of personalized cancer vaccines.
论文信息
- 作者
- Vlachostergios PJ
- 单位
- Department of Medical Oncology, IASO Thessalias Hospital, 41500 Larissa, Greece.Greece
- 文献类型
- 综述
- 期刊
- Exploration of targeted anti-tumor therapy2025
- 原文标识
- PubMed 41322103 · DOI 10.37349/etat.2025.1002350